Top

International Journal of Clinical Oncology

Published in:

01-08-2018 | Original Article

Oncologic outcomes for open and laparoscopic radical nephroureterectomy in patients with upper tract urothelial carcinoma

Authors: Koichi Kido, Shingo Hatakeyama, Naoki Fujita, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Ikuya Iwabuchi, Masaru Ogasawara, Toshiaki Kawaguchi, Chikara Ohyama

Published in: International Journal of Clinical Oncology | Issue 4/2018

Abstract

Background

Oncologic benefits of laparoscopic radical nephroureterectomy (LNU) are unclear. We aimed to evaluate the impact of surgical approach for radical nephroureterectomy on oncologic outcomes in patients with locally advanced upper tract urothelial carcinoma (UTUC).

Methods

Of 426 patients who underwent radical nephroureterectomy at five medical centers between February 1995 and February 2017, we retrospectively investigated oncological outcomes in 229 with locally advanced UTUC (stages cT3-4 and/or cN+). The surgical approach was classified as open nephroureterectomy (ONU) or LNU, and oncologic outcomes, including intravesical recurrence-free survival (RFS), visceral RFS, cancer-specific survival (CSS), and overall survival (OS), were compared between the groups. The inverse probability of treatment weighting (IPTW)-adjusted Cox-regression analyses was performed to evaluate the impact of LNU on the prognosis.

Results

Of the 229 patients, 48 (21%) underwent LNU. There were significant differences in patient backgrounds, including preoperative renal function, lymph-node involvement, lymphovascular invasion, and surgical margins, between the groups. Before the background adjustment, intravesical RFS, visceral RFS, CSS, and OS were significantly inferior in the ONU group than in the LNU group. However, in the IPTW-adjusted Cox-regression analysis, no significant differences were observed in intravesical RFS (hazard ratio [HR], 0.65; P = 0.476), visceral RFS (HR, 0.46; P = 0.109), CSS (HR, 0.48; P = 0.233), and OS (HR, 0.40; P = 0.147).

Conclusion

Surgical approaches were not independently associated with prognosis in patients with locally advanced UTUC.

Roupret M, Babjuk M, Comperat E et al (2015) European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 68(5):868–879. https://doi.org/10.1016/j.eururo.2015.06.044 CrossRefPubMed

Miyazaki J, Nishiyama H, Fujimoto H et al (2016) Laparoscopic versus open nephroureterectomy in muscle-invasive upper tract urothelial carcinoma: subanalysis of the Multi-Institutional National Database of the Japanese Urological Association. J Endourol 30(5):520–525. https://doi.org/10.1089/end.2015.0757 CrossRefPubMed

Capitanio U, Shariat SF, Isbarn H et al (2009) Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol 56(1):1–9. https://doi.org/10.1016/j.eururo.2009.03.072 CrossRefPubMed

Simone G, Papalia R, Guaglianone S et al (2009) Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. Eur Urol 56(3):520–526. https://doi.org/10.1016/j.eururo.2009.06.013 CrossRefPubMed

Ariane MM, Colin P, Ouzzane A et al (2012) Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol 19(1):301–308. https://doi.org/10.1245/s10434-011-1841-x CrossRefPubMed

Ni S, Tao W, Chen Q et al (2012) Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol 61(6):1142–1153. https://doi.org/10.1016/j.eururo.2012.02.019 CrossRefPubMed

Fairey AS, Kassouf W, Estey E et al (2013) Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. BJU Int 112(6):791–797. https://doi.org/10.1111/j.1464-410X.2012.11474.x CrossRefPubMed

Zhang S, Luo Y, Wang C et al (2016) Long-term oncologic outcomes of laparoscopic nephroureterectomy versus open nephroureterectomy for upper tract urothelial carcinoma: a systematic review and meta-analysis. PeerJ 4:e2063. https://doi.org/10.7717/peerj.2063 CrossRefPubMedPubMedCentral

Kamihira O, Hattori R, Yamaguchi A et al (2009) Laparoscopic radical nephroureterectomy: a multicenter analysis in Japan. Eur Urol 55(6):1397–1407. https://doi.org/10.1016/j.eururo.2009.03.003 CrossRefPubMed

10.

Kim HS, Ku JH, Jeong CW et al (2016) Laparoscopic radical nephroureterectomy is associated with worse survival outcomes than open radical nephroureterectomy in patients with locally advanced upper tract urothelial carcinoma. World J Urol 34(6):859–869. https://doi.org/10.1007/s00345-015-1712-3 CrossRefPubMed

11.

Oya M, Kikuchi E (2015) Evidenced-based clinical practice guideline for upper tract urothelial carcinoma (summary–Japanese Urological Association, 2014 edition). Int J Urol 22(1):3–13. https://doi.org/10.1111/iju.12630 CrossRefPubMed

12.

Matsuo S, Imai E, Horio M et al (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982–992. https://doi.org/10.1053/j.ajkd.2008.12.034 CrossRefPubMed

13.

Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer., ebrary Inc. (2009) TNM classification of malignant tumours. 7th edn. Wiley-Blackwell, Chichester, West Sussex, UK; Hoboken, NJ

14.

Messer JC, Terrell JD, Herman MP et al (2013) Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol 31(6):904–908. https://doi.org/10.1016/j.urolonc.2011.07.011 CrossRefPubMed

15.

Ito Y, Kikuchi E, Tanaka N et al (2011) Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol 185(5):1621–1626. https://doi.org/10.1016/j.juro.2010.12.035 CrossRefPubMed

16.

Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–196. https://doi.org/10.1097/SLA.0b013e3181b13ca2 CrossRefPubMed

17.

Galsky MD, Hahn NM, Rosenberg J et al (2011) A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12(3):211–214. https://doi.org/10.1016/S1470-2045(10)70275-8 CrossRefPubMed

18.

Fang Z, Li L, Wang X et al (2014) Total retroperitoneal laparoscopic nephroureterectomy with bladder-cuff resection for upper urinary tract transitional cell carcinoma. J Invest Surg 27(6):354–359. https://doi.org/10.3109/08941939.2014.930214 CrossRefPubMed

19.

Kubota Y, Nakaigawa N, Committee for Establishment of the Clinical Practice Guideline for the Management of Bladder C, the Japanese Urological A (2016) Essential content of evidence-based clinical practice guidelines for bladder cancer: the Japanese Urological Association 2015 update. Int J Urol 23(8):640–645. https://doi.org/10.1111/iju.13141 CrossRefPubMed

20.

Kusaka A, Hatakeyama S, Hosogoe S et al (2017) Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer. Oncotarget. https://doi.org/10.18632/oncotarget.19043 CrossRefPubMedPubMedCentral

21.

Kusaka A, Hatakeyama S, Hosogoe S et al (2017) Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer. Med Oncol 34(5):90. https://doi.org/10.1007/s12032-017-0955-9 CrossRefPubMed

22.

Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34(28):3661–3679. https://doi.org/10.1002/sim.6607 CrossRefPubMedPubMedCentral

23.

Walton TJ, Novara G, Matsumoto K et al (2011) Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int 108(3):406–412. https://doi.org/10.1111/j.1464-410X.2010.09826.x CrossRefPubMed

24.

Hosogoe S, Hatakeyama S, Kusaka A et al (2017) Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma. Eur Urol Focus. https://doi.org/10.1016/j.euf.2017.03.013 PubMedCrossRef

25.

Kubota Y, Hatakeyama S, Tanaka T et al (2017) Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget. https://doi.org/10.18632/oncotarget.21551 CrossRefPubMedPubMedCentral

Title: Oncologic outcomes for open and laparoscopic radical nephroureterectomy in patients with upper tract urothelial carcinoma
Authors: Koichi Kido
Shingo Hatakeyama
Naoki Fujita
Hayato Yamamoto
Yuki Tobisawa
Tohru Yoneyama
Takahiro Yoneyama
Yasuhiro Hashimoto
Takuya Koie
Ikuya Iwabuchi
Masaru Ogasawara
Toshiaki Kawaguchi
Chikara Ohyama
Publication date: 01-08-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1248-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2018

Complications within 90 days after radical cystectomy for bladder cancer: results of a multicenter prospective study in Japan

Five-year outcomes following hypofractionated stereotactic radiotherapy delivered in five fractions for acoustic neuromas: the mean cochlear dose may impact hearing preservation

Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status

Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?

Recent advances in medical therapy for metastatic urothelial cancer

The cumulative incidence and risk factors of postoperative inguinal hernia in patients undergoing radical prostatectomy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer